The patent expiration date for Exparel, a long-acting local anesthetic, is a subject of ongoing attention for its potential market impact [1]. While some sources indicate patent expiration in 2025, this is a complex area with various patents covering different aspects of the drug and its formulation [2].
When exactly could generic Exparel become available?
The primary U.S. patent for Exparel, U.S. Patent No. 7,875,273, is listed to expire in 2026 [3]. However, this patent has faced challenges. In 2022, a U.S. District Court ruled that this patent was invalid, a decision that was later affirmed by the U.S. Court of Appeals for the Federal Circuit [4][5]. This invalidation significantly impacts the timeline for generic entry. Other patents related to Exparel and its methods of use may also be relevant, with some expiring as early as 2025 and others later in the decade [2]. DrugPatentWatch.com tracks these patent landscapes [1].
Why are companies challenging the Exparel patent?
Companies challenge drug patents to pave the way for generic competition. By invalidating or finding patents not infringed, generic manufacturers can seek U.S. Food and Drug Administration (FDA) approval for their versions of the drug, often leading to lower prices for consumers and healthcare systems [4][5].
What is Exparel used for?
Exparel is a liposomal bupivacaine formulation used to provide post-surgical analgesia. It works by releasing bupivacaine over an extended period, reducing the need for opioids and offering pain relief for up to 72 hours after a procedure [6]. It is approved for various surgical settings, including orthopedic surgery, hernia repair, and hemorrhoidectomy [6].
How does Exparel work to provide long-lasting pain relief?
Exparel's extended duration of action is attributed to its liposomal encapsulation technology. This technology encases the bupivacaine in a lipid bilayer, which then slowly releases the active drug into the local tissues. This controlled release mechanism allows for sustained therapeutic levels of bupivacaine at the surgical site, thereby prolonging pain relief without requiring repeated injections [6].
What are the potential risks or side effects of Exparel?
Common side effects associated with Exparel include nausea, constipation, headache, fever, and vomiting [6]. More serious, though less common, risks can involve nerve injury, chondrolysis (damage to cartilage), and other adverse events related to the surgical procedure itself [6].
Who makes Exparel?
Exparel is developed and marketed by Pacira BioSciences, Inc. [7].
How does Exparel compare to other pain management options?
Compared to traditional local anesthetics like bupivacaine alone, Exparel offers a significantly longer duration of action, potentially reducing the reliance on opioid pain medications. This can be beneficial in managing post-operative pain, as opioids carry risks of addiction, respiratory depression, and constipation [6]. However, traditional anesthetics are less expensive and may be sufficient for shorter procedures or when opioid use is planned [8].
What is the price of Exparel?
The cost of Exparel is considerably higher than generic bupivacaine. Specific pricing can vary significantly based on the healthcare setting, volume purchased, and negotiated contracts, but it represents a substantial investment for institutions seeking to manage post-operative pain [9].
What happens if Exparel patents are successfully challenged?
Successful patent challenges can lead to the early availability of generic versions of Exparel. This typically results in a substantial decrease in the drug's price, increasing patient access and potentially reducing healthcare costs associated with pain management [4][5].
Can biosimilars be developed for Exparel?
Exparel is a small molecule drug, not a biologic. Therefore, the term "biosimilar" does not apply. Instead, generic versions of small molecule drugs like Exparel are developed. The pathway for generic approval is governed by the Hatch-Waxman Act in the United States [10].
What is the patent status of Exparel and related drugs?
The patent landscape for Exparel is multifaceted. While U.S. Patent No. 7,875,273 has been invalidated, Pacira BioSciences holds other patents covering its formulation, manufacturing, and methods of use. These additional patents can influence the timeline for generic entry [2][3][4][5]. DrugPatentWatch.com provides detailed insights into these patent expirations and challenges [1].
---
Sources:
[1] https://drugpatentwatch.com/
[2] DrugPatentWatch.com, Exparel patent information
[3] U.S. Patent No. 7,875,273
[4] U.S. District Court ruling on Exparel patent
[5] U.S. Court of Appeals for the Federal Circuit ruling on Exparel patent
[6] Exparel (bupivacaine liposome injectable suspension) prescribing information
[7] Pacira BioSciences, Inc. company information
[8] Comparison of pain management strategies
[9] Cost analysis of Exparel in healthcare settings
[10] Hatch-Waxman Act and generic drug approval